我国各地医保目录中抗肿瘤药物类基本药物的收载情况分析

发布时间：2018-02-09 00:52

本文关键词： 抗肿瘤药物国家基本药物目录医保目录收载　出处：《中国药房》2015年30期 　论文类型：期刊论文

【摘要】：目的:为促进基本药物优先使用、国家及地方医保目录中抗肿瘤药物的科学遴选提供参考。方法:登陆我国北京、上海、广州、南京、武汉、西安、成都、沈阳、济南、贵阳10个城市的人力资源和社会保障局网站,下载各地医保目录,对其中的抗肿瘤药物(包括24种国家基本药物品种)的收载情况进行统计和分析。结果:医保目录收载的抗肿瘤药物品种数在100种以上的有5个城市,其中上海共有255种,远远多于其他城市;医保目录甲类药物除北京多达67种抗肿瘤药物外,其他城市数量均接近30种,而乙类药物上海最多,北京最少。24种抗肿瘤药物类基本药物在10个城市的医保目录中均有收载,但根据其剂型不同,在不同城市医保目录中归类有所差异,其中阿糖胞苷(注射剂)、阿霉素/多柔比星(注射剂)、白消安(口服常释剂型)、氟尿嘧啶(口服常释剂型、注射剂)、环磷酰胺(口服常释剂型、注射剂)、甲氨蝶呤(口服常释剂型、注射剂)、顺铂(注射剂)等16种药物的部分剂型在所有城市均归为甲类药物;奥沙利铂(注射剂)、紫杉醇(注射剂)在所有城市均归为乙类药物;白消安、氟尿嘧啶、环磷酰胺、甲氨蝶呤等的其他剂型仅在上海归为乙类药物。结论:各地区医保目录中抗肿瘤药物类基本药物分布有一定差异,发达城市品种数相对较多,欠发达城市品种数相对较少。建议各地参照当地肿瘤流行病学特点和经济状况,合理遴选抗肿瘤药物类基本药物纳入医保目录,并合理调整医保目录甲类与乙类药物比例,以保证基本用药和药品报销。
[Abstract]:Objective: to provide a reference for the scientific selection of anti-tumor drugs in the national and local medical insurance catalogue in order to promote the priority use of essential drugs. Methods: Beijing, Shanghai, Guangzhou, Nanjing, Wuhan, Xi'an, Chengdu, Shenyang, Jinan, China. The websites of the Human Resources and Social Security Bureau in 10 cities of Guiyang, Statistics and analysis of the loading status of anti-tumor drugs (including 24 national essential drug varieties). Results: there are 5 cities with more than 100 kinds of anti-tumor drugs in the medical insurance catalogue, of which 255 are in Shanghai. This is far more than in other cities; the number of category A drugs in the health care catalogue is close to 30 in addition to the 67 anti-tumor drugs in Beijing, while the number of category B drugs in Shanghai is the largest. There are at least 24 essential anti-tumor drugs in Beijing, all of which are included in the medical insurance catalogue in 10 cities, but according to their dosage forms, they are classified differently in different city health insurance catalogues. Cytarabine (injection), doxorubicin / doxorubicin (injection), Paixuan (oral release form), fluorouracil (oral form, injection, cyclophosphamide), Injection, methotrexate (oral normal release dosage form, injection, Cisplatin (injection) and other 16 drug formulations are classified as A drugs in all cities; " Oxaliplatin (injection), paclitaxel (injection) is classified as class B in all cities; oxaliplatin, fluorouracil, cyclophosphamide, Other formulations of methotrexate are classified only as B drugs in Shanghai. Conclusion: there are some differences in the distribution of essential antitumor drugs in the medical insurance catalogue of different regions, and there are relatively many kinds of antitumor drugs in developed cities. The number of varieties in less developed cities is relatively small. It is suggested that according to the epidemiological characteristics and economic situation of local tumors, the essential drugs of anti-tumor drugs should be reasonably selected for inclusion in the catalogue of medical insurance, and the proportion of A and B drugs in the catalogue of medical insurance should be adjusted rationally. To ensure basic medication and drug reimbursement.
【作者单位】：中国医学科学院肿瘤医院药剂科;
【分类号】：R95

【参考文献】